Vitamin D, Glucose Control and Insulin Sensitivity in African-Americans
- Conditions
- Type 2 Diabetes
- Interventions
- Dietary Supplement: cholecalciferolOther: microcrystalline cellulose
- Registration Number
- NCT00784511
- Lead Sponsor
- Tufts University
- Brief Summary
North American blacks tend to have low blood levels of vitamin D because pigmentation blocks vitamin D production in the skin. They also have higher rates of developing type 2 diabetes and higher rates of complications from the disease compared with whites. Although there is compelling evidence that adequate vitamin D may reduce the risk for type 2 diabetes in whites, recent evidence from a national survey demonstrated an association of vitamin D with diabetes in whites but not in blacks. However, the central hypothesis of this study is that providing enough supplemental vitamin D to blacks (raising their blood levels higher than that of most participants in the survey) will improve blood measures related to diabetes risk. The proposed study is a 12-week randomized, double-blind, placebo-controlled experiment designed to examine the effect of vitamin D supplementation (100 μg/d ) on insulin secretion, insulin sensitivity and glucose control in pre-diabetic black men and women aged 40 and older.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- African-American by self designation
- Glucose intolerance defined as FPG ≥ 100 mg/dl or A1c ≥ 5.8%
- BMI 25.0-39.9
- Age 40 or older
Medical Conditions
-
Diabetes potentially requiring pharmacotherapy, defined as A1c > 7%
-
Uncontrolled thyroid disease
-
Current parathyroid, liver or kidney disease
-
Renal stone within 5 years
-
Sarcoidosis, current pancreatitis, active tuberculosis, hemiplegia, gout
-
Inflammatory bowel disease, colostomy, malabsorption
-
Cancer other than basal cell skin cancer within 5 years
-
Uncontrolled arrhythmia in past year
-
Albinism or other condition associated with reduced skin pigmentation
-
Pregnancy over the last 1 year
-
Intent to become pregnant
-
Menopause onset within 1 year
-
Any other unstable medical condition Laboratory Tests
-
Fasting plasma glucose < 100
-
Hemoglobin A1c > 7%
-
Laboratory evidence of liver disease (e.g. AST > 70 U/L or ALT > 72 IU/L)
-
Laboratory evidence of kidney disease (e.g. estimated glomerular filtration rate < 60 ml/min/1.73 m2).
-
Elevated spot urine calcium to creatinine ratio > 0.38 mg/dl*
-
Abnormal serum calcium (serum calcium > 10.5 mg/dl)
-
Anemia (Hematocrit < 36% in men, <33% in women) Medications (use in past three months)
-
Estrogen or testosterone
-
Prescription vitamin D
-
Lithium
-
Oral corticosteroids
-
Anti-seizure medications
-
Unstable doses of psychotropics or phenothiazines
-
Cholestyramine Supplements (current use - may discontinue after screening)
-
Vitamin D supplements, cod liver oil, calcium supplements Other
-
Body mass index less <25 or > 39.9
-
Consumption of more than 14 alcoholic drinks per week
-
Inability to attend all three study visits as scheduled
-
Inability to provide written informed consent
-
age < 40 years
-
not African-American (by self-designation)
-
Participation in another research intervention study
- corresponds to a 24-hour urinary calcium excretion > 400 mg
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 vitamin D3 cholecalciferol vitamin D3, 4000 IU/d 2 microcrystalline cellulose placebo
- Primary Outcome Measures
Name Time Method Insulin secretion rate 12 weeks Insulin sensitivity index 12 weeks 2-hr post load glucose 12 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
🇺🇸Boston, Massachusetts, United States